Perspective
Volume 16:12, 2022

Journal of Molecular and Genetic Medicine

ISSN: 1747-0862 Open Access

Short Notes on Alkaptonuria Inhibitors with Possibility of Treatment

Michael Ethan*

Department of Molecular Cell Biology, Katholieke University, Leuven, Belgium

Introduction

Alkaptonuria is a rare metabolic disorder that results in the accumulation of homogentisic acid (HGA) in the body. This build-up of HGA can lead to a range of symptoms, including darkening of the skin, joint problems, and cardiac complications. Currently, there is no cure for alkaptonuria, and treatment is mainly supportive. However, recent advances in computational methods have provided new opportunities to identify potential inhibitors for the treatment of alkaptonuria. One approach to identifying potential inhibitors is to screen large libraries of compounds for their ability to inhibit the enzyme responsible for the breakdown of HGA, called homogentisate 1,2-dioxygenase (HGD). Inhibiting this enzyme would reduce the amount of HGA produced in the body and could potentially alleviate symptoms.

Another approach is to target the metabolic pathways involved in the breakdown of HGA. For example, researchers could look for compounds that increase the expression of enzymes involved in the breakdown of HGA or reduce the expression of enzymes involved in its production. Computer-aided drug design (CADD) is another approach that can be used to identify potential inhibitors. CADD uses computational methods to predict the interactions between a drug molecule and its target protein, allowing researchers to screen large databases of compounds and identify those with the highest likelihood of binding to the target protein.

In addition to these approaches, researchers could also investigate natural compounds that have been traditionally used to treat joint pain and arthritis, as these may have potential as inhibitors for the treatment of alkaptonuria. Overall, the identification of potential inhibitors for the treatment of alkaptonuria requires a multidisciplinary approach that incorporates both experimental and computational methods. In this, we will discuss an integrated in silico computational strategy for the identification of potential inhibitors for the treatment of alkaptonuria [1-3]. The strategy involves several steps, including molecular docking, molecular dynamics simulations, and free energy calculations.

Description

Preparation of protein and ligand structures

The first step in the computational strategy is to prepare the protein and ligand structures. In this case, the protein of interest is the enzyme homogentisate 1,2-dioxygenase (HGD), which is responsible for breaking down HGA in the body. The ligands are small molecules that have the potential to inhibit the activity of HGD.

The protein structure is obtained from the Protein Data Bank (PDB) and is prepared for molecular docking by removing any crystallographic waters, adding missing atoms, and optimizing the hydrogen bond network. The ligand structures are obtained from the ZINC database and are prepared for docking by adding hydrogen atoms and optimizing the geometry.

Molecular docking

The next step in the strategy is molecular docking, which involves the prediction of the binding mode and affinity of the ligands to the protein. In this case, we use AutoDock Vina, which is widely used docking software that uses a search algorithm to explore the conformational space of the ligand and protein.

The docking results are analyzed to identify potential inhibitors based on their predicted binding affinity and binding mode. The top-scoring compounds are then selected for further analysis [4,5].

Molecular dynamics simulations

The third step in the strategy is molecular dynamics (MD) simulations, which are used to study the behavior of the ligand-protein complex over time. MD simulations involve the integration of Newton's equations of motion to calculate the movement of atoms and molecules in the system. In this case, we use the GROMACS software package to perform MD simulations. The ligand-protein complex is solvated in a box of water molecules and neutralized with counterions. The system is then energy minimized and equilibrated before running the production MD simulation. The MD simulation is run for several nanoseconds, and the trajectory is analyzed to identify the stable binding modes and interactions between the ligand and protein.

Conclusion

The final step in the strategy is free energy calculations, which are used to predict the binding affinity of the ligand to the protein more accurately. Free energy calculations involve the calculation of the difference in free energy between the bound and unbound states of the ligand-protein complex. In this case, we use the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) method to perform free energy calculations. The method calculates the free energy of the system using molecular mechanics, Poisson-Boltzmann electrostatics, and surface area terms. The free energy calculations are used to rank the potential inhibitors based on their predicted binding affinity to the protein. Using the integrated in silico computational strategy, we identified several potential inhibitors for the treatment of alkaptonuria. The top-scoring compounds from the molecular docking analysis were further analyzed using MD simulations and free energy calculations. The results of the MD simulations showed that the top-scoring compounds formed stable binding modes with the protein and had favorable interactions.

References

1. Deperas, Joanna, Marta Szłuińska, Marta Deperas-Kaminska and Alan Edwards, et al. "CABAS: A freely available PC program for fitting calibration curves in chromosome aberration dosimetry." *Radiat Prot Dosim* 124 (2007): 115-123.
2. Koppen, G., G. Verheyen, A. Maes and U. Van Gorp, et al. "A battery of DNA effect biomarkers to evaluate environmental exposure of Flemish adolescents." *J Appl Toxicol* 273 (2007): 238-246.

***Address for Correspondence:** Michael Ethan, Department of Molecular Cell Biology, Katholieke University, Leuven, Belgium, E-mail: ethanmich@gmail.com*

***Copyright:** © 2022 Ethan M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*

Received: 01 December, 2022, Manuscript No: jmgm-23-92282; **Editor Assigned:** 03 December, 2022, Pre-QC No. P-92282; **Reviewed:** 15 December, 2022, QC No. Q-92282; **Revised:** 20 December, 2022, Manuscript No: R-92282; **Published:** 27 December, 2022, DOI: 10.37421/1747-0862.2022.16.591

3. Brambilla, Marco, Barbara Cannillo, Andrea Alessio and Roberta Matheoud, et al. "Patients undergoing multiphase CT scans and receiving a cumulative effective dose of≥ 100 mSv in a single episode of care." *Eur Radiol* 31 (2021): 4452-4458.

4. Hansson, Oskar. "Biomarkers for neurodegenerative diseases." *Nat med* 27 (2021): 954-963.

5. Paulsen, Jane S., Megan M. Smith, Jeffrey D. Long and Predict HD et al. "Cognitive decline in prodromal Huntington disease: Implications for clinical trials." *J Neurol Neurosurg Psychiatry* 84 (2013): 1233-1239.

How to cite this article: Ethan, Michael. "Short Notes on Alkaptonuria Inhibitors with Possibility of Treatment." J Mol Genet Med 16 (2022): 591.